Last reviewed · How we verify
Preservative free artificial tear
Preservative-free artificial tears lubricate and protect the ocular surface by supplementing natural tear film.
Preservative-free artificial tears lubricate and protect the ocular surface by supplementing natural tear film. Used for Dry eye disease / Keratoconjunctivitis sicca, Ocular surface protection and lubrication.
At a glance
| Generic name | Preservative free artificial tear |
|---|---|
| Also known as | Optive UD®, Allergan, Irvine, USA |
| Sponsor | Fundação Altino Ventura |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
This product mimics the composition and function of natural tears to provide moisture and protection to the cornea and conjunctiva. By eliminating preservatives, it reduces the risk of ocular irritation and toxicity associated with preservative agents, making it suitable for frequent use and sensitive eyes. The formulation helps restore tear film stability and reduce symptoms of dry eye disease.
Approved indications
- Dry eye disease / Keratoconjunctivitis sicca
- Ocular surface protection and lubrication
Common side effects
- Transient blurred vision
- Mild ocular irritation
- Allergic reaction (rare)
Key clinical trials
- SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease (PHASE4)
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST) (NA)
- Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye (PHASE2)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preservative free artificial tear CI brief — competitive landscape report
- Preservative free artificial tear updates RSS · CI watch RSS
- Fundação Altino Ventura portfolio CI